An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg Twice Daily (BID) in Combination With Standard of Care in Patients With Active Lupus Nephritis
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Voclosporin (Primary) ; Corticosteroids; Mycophenolate mofetil
- Indications Lupus nephritis
- Focus Biomarker; Proof of concept; Therapeutic Use
- Acronyms AURION
- Sponsors Aurinia Pharmaceuticals
Most Recent Events
- 17 Mar 2021 Number of Participants With Reduction or Normalization of Anti ds DNA, C3 and C4, have been introduced as new primary end-points in addition to the existing one (Urine Protein/Creatinine Ratio (UPCR)).
- 18 Sep 2017 Status changed from active, no longer recruiting to completed.
- 27 Mar 2017 Results at week 48 published in an Aurinia Pharmaceuticals media release.